Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?

The FDA extended its review of Exelixis' zanzalintinib-plus-Tecentriq NDA for metastatic colorectal cancer by three months, moving the action date to March 3, 2027 from December 3, 2026 after updated safety and efficacy data were deemed a major amendment. EXEL shares have fallen 2.8% since the announcement, although they remain up 29.5% year to date versus 6.3% for the industry. The delay pushes out Exelixis' key near-term pipeline catalyst and its strategy to establish a second commercial oncology franchise beyond Cabometyx.

Analysis

The meaningful issue is not three months of lost sales but a higher probability that the FDA is interrogating the durability or safety package after updated data. Because the CRC program is intended to validate Exelixis' post-Cabometyx growth architecture, a prolonged review can compress the multiple assigned to its pipeline even if the ultimate decision is positive. Near term, sell-side models may only trim 2027 revenue modestly; the larger 6-18 month risk is that slower-than-expected uptake in newer Cabometyx indications and a delayed second franchise expose concentration risk before zanzalintinib can contribute material cash flow.

The market may be underpricing read-through to zanzalintinib's broader development program. A regulator focused on a combination regimen's updated safety/efficacy data does not automatically invalidate RCC or adjuvant CRC opportunities, but it raises the evidence threshold and makes upcoming trial design, discontinuation rates, and subgroup consistency more consequential. MRK's economic exposure is limited relative to Keytruda/Welireg, so any sympathy move in MRK should be shallow; the more relevant beneficiary of EXEL de-risking is competing RCC franchise owners, particularly Merck's Welireg, if zanzalintinib differentiation weakens.

Consensus may treat the delay as routine because the application was extended only one review cycle. That is plausible, but the asymmetry remains unfavorable into the action date: approval likely restores only deferred value, whereas a complete response letter would force a materially longer revenue gap and impair confidence in the platform. The key falsifiers are FDA approval without restrictive labeling, no material deterioration in updated safety disclosures, and management maintaining 2027-28 zanzalintinib revenue expectations at the next earnings call.

Key Decisions for Investors

• Maintain an underweight in EXEL through the next earnings call and FDA decision window; do not add on the initial modest decline unless management quantifies the amendment and preserves launch-year guidance. A complete response letter is the downside catalyst; clean approval with a standard label is the stop condition.
• For event exposure, use a defined-risk bearish EXEL put spread spanning March 2027 rather than an outright short: buy a near-ATM put and sell a 15-20% out-of-the-money put. This targets multiple compression from regulatory uncertainty while capping premium loss if approval clears cleanly.
• Consider a 3-6 month relative-value pair of long MRK versus short EXEL in equal beta-adjusted dollars. MRK retains strategic upside from its RCC combination ecosystem while EXEL bears the direct regulatory and franchise-concentration risk; exit if EXEL provides reassuring amendment detail or the relative spread widens materially before a new fundamental catalyst.
• Monitor EXEL's Cabometyx prescription trends and NET uptake quarterly. If core-franchise growth reaccelerates enough to fund pipeline investment without revised guidance, the delay becomes largely a timing issue and the bearish thesis should be reduced.